Back to top
more

McKesson (MCK)

(Real Time Quote from BATS)

$709.70 USD

709.70
30,414

-1.24 (-0.17%)

Updated Aug 5, 2025 10:28 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (59 out of 246)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's Why You Should Retain Fresenius Medical (FMS) for Now

by Zacks Equity Research

Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.

Zacks Equity Research

Masimo (MASI) Gets De Novo for Novel Oxygen Status Index ORi

by Zacks Equity Research

Masimo's (MASI) ORi parameter gets De Novo from the FDA, providing option for continuous monitoring of oxygen level in surgical patients leading to better management of hyperoxia.

Zacks Equity Research

QuidelOrtho (QDEL) Reports Solid Preliminary Q3 Revenues

by Zacks Equity Research

QuidelOrtho's (QDEL) revenue growth in the third quarter is likely to have been boosted by continued strength in its non-respiratory product sales.

Zacks Equity Research

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

Reasons to Retain The Cooper Companies (COO) in Your Portfolio

by Zacks Equity Research

The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is concerning.

Zacks Equity Research

Fresenius Medical (FMS) Sinks on Potential Rise in Competition

by Zacks Equity Research

Fresenius Medical's (FMS) shares decline more than 17% on Wednesday following news of the successful clinical trial of a competing drug in preventing kidney disease.

Zacks Equity Research

McKesson (MCK) Upgraded to Strong Buy: Here's What You Should Know

by Zacks Equity Research

McKesson (MCK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Equity Research

Merit Medical's (MMSI) New Launch to Expand Its Product Suite

by Zacks Equity Research

Merit Medical's (MMSI) latest addition to its Vascular portfolio is expected to significantly improve patient outcomes.

Zacks Equity Research

How to Find Strong Buy Medical Stocks Using the Zacks Rank

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Rank.

Zacks Equity Research

Is Cardinal Health (CAH) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Reasons to Add Cardinal Health (CAH) in Your Portfolio

by Zacks Equity Research

Cardinal Health (CAH) continues to gain traction from solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.

Zacks Equity Research

NextGen's (NXGN) AI-Based Ambient Assist to Expedite Care Plans

by Zacks Equity Research

NextGen's (NXGN) Ambient Assist will help reduce significant time by summarizing appointments and preparing care plans using AI-driven technology in real time.

Zacks Equity Research

Masimo's (MASI) LiDCO to Boost Hemodynamic Monitoring Post CE Mark

by Zacks Equity Research

Masimo's (MASI) LiDCO is likely to offer clinicians a BIC solution designed to provide a more complete picture of oxygen delivery.

Zacks Equity Research

3 Reasons to Add Surmodics (SRDX) Stock to Your Portfolio

by Zacks Equity Research

Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.

Indrajit Bandyopadhyay headshot

4 Stocks to Buy From the Prospering Dental Supplies Industry

by Indrajit Bandyopadhyay

Here we discuss four stocks from the Dental Supplies industry that are likely to earn wealth for investors. These include MCK, WST, ALGN and HSIC.

Zacks Equity Research

3 Reasons to Retain Inogen (INGN) Stock in Your Portfolio

by Zacks Equity Research

Inogen's (INGN) potential in the POC space and a strong product portfolio raise optimism about the stock.

Zacks Equity Research

Veradigm (MDRX)-FDB Vela to Enhance Pharmacy Connectivity

by Zacks Equity Research

Veradigm's (MDRX) latest progress with FDB Vela is likely to offer prescribers and patients greater choice and cost transparency.

Zacks Equity Research

DexCom (DXCM) to Launch Latest CGM System G7 in Canada

by Zacks Equity Research

DexCom's (DXCM) G7 CGM System (launched in Canada) is expected to combine simplicity and power, thereby providing a better way to manage diabetes.

Zacks Equity Research

Here's How Much a $1000 Investment in McKesson Made 10 Years Ago Would Be Worth Today

by Zacks Equity Research

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

Zacks Equity Research

Three Reasons to Add PacBio (PACB) Stock to Your Portfolio

by Zacks Equity Research

PacBio's (PACB) product development activities raise optimism about the stock.

Zacks Equity Research

OPKO Health (OPK) Gets BARDA Contract to Combat Antibody Threats

by Zacks Equity Research

OPKO Health's (OPK) latest awarded funding is likely to enable the development of novel multispecific antibodies against viral infectious disease threats.

Zacks Equity Research

Here's Why You Should Add McKesson (MCK) to Your Portfolio

by Zacks Equity Research

McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.

Zacks Equity Research

Reasons to Add Inari Medical (NARI) Stock to Your Portfolio

by Zacks Equity Research

Inari Medical (NARI) continues to benefit from its commitment to understand the venous system. However, its dependency on adoption of products is a concern.

Zacks Equity Research

3 Reasons to Add Merit Medical (MMSI) Stock to Your Portfolio

by Zacks Equity Research

Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.

Zacks Equity Research

Here's Why You Should Retain Glaukos (GKOS) Stock for Now

by Zacks Equity Research

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.